Literature DB >> 28031164

Improvement in 5-year mortality in incident rheumatoid arthritis compared with the general population-closing the mortality gap.

Diane Lacaille1,2, J Antonio Avina-Zubieta1,2, Eric C Sayre1, Michal Abrahamowicz3.   

Abstract

OBJECTIVE: Excess mortality in rheumatoid arthritis (RA) is expected to have improved over time, due to improved treatment. Our objective was to evaluate secular 5-year mortality trends in RA relative to general population controls in incident RA cohorts diagnosed in 1996-2000 vs 2001-2006.
METHODS: We conducted a population-based cohort study, using administrative health data, of all incident RA cases in British Columbia who first met RA criteria between January 1996 and December 2006, with general population controls matched 1:1 on gender, birth and index years. Cohorts were divided into earlier (RA onset 1996-2000) and later (2001-2006) cohorts. Physician visits and vital statistics data were obtained until December 2010. Follow-up was censored at 5 years to ensure equal follow-up in both cohorts. Mortality rates, mortality rate ratios and HRs for mortality (RA vs controls) using proportional hazard models adjusting for age, were calculated. Differences in mortality in RA versus controls between earlier and later incident cohorts were tested via interaction between RA status (case/control) and cohort (earlier/later).
RESULTS: 24 914 RA cases and controls experienced 2747 and 2332 deaths, respectively. Mortality risk in RA versus controls differed across incident cohorts for all-cause, cardiovascular diseases (CVD) and cancer mortality (interactions p<0.01). A significant increase in mortality in RA versus controls was observed in earlier, but not later, cohorts (all-cause mortality adjusted HR (95% CI): 1.40 (1.30 to 1.51) and 0.97 (0.89 to 1.05), respectively).
CONCLUSIONS: In our population-based incident RA cohort, mortality compared with the general population improved over time. Increased mortality in the first 5 years was observed in people with RA onset before, but not after, 2000. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.

Entities:  

Keywords:  Epidemiology; Outcomes research; Rheumatoid Arthritis

Mesh:

Year:  2016        PMID: 28031164      PMCID: PMC5526676          DOI: 10.1136/annrheumdis-2016-209562

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  69 in total

1.  Guidelines for the management of rheumatoid arthritis: 2002 Update.

Authors: 
Journal:  Arthritis Rheum       Date:  2002-02

2.  Modeling smoking history: a comparison of different approaches.

Authors:  Karen Leffondré; Michal Abrahamowicz; Jack Siemiatycki; Bernard Rachet
Journal:  Am J Epidemiol       Date:  2002-11-01       Impact factor: 4.897

3.  The epidemiology of rheumatoid arthritis in Ontario, Canada.

Authors:  Jessica Widdifield; J Michael Paterson; Sasha Bernatsky; Karen Tu; George Tomlinson; Bindee Kuriya; J Carter Thorne; Claire Bombardier
Journal:  Arthritis Rheumatol       Date:  2014-04       Impact factor: 10.995

4.  Statin discontinuation and risk of acute myocardial infarction in patients with rheumatoid arthritis: a population-based cohort study.

Authors:  Mary A De Vera; Hyon Choi; Michal Abrahamowicz; Jacek Kopec; Maria Victoria Goycochea-Robles; Diane Lacaille
Journal:  Ann Rheum Dis       Date:  2011-03-06       Impact factor: 19.103

5.  Decreasing mortality in patients with rheumatoid arthritis: results from a large population based cohort in Sweden, 1964-95.

Authors:  Lena Björnådal; Eva Baecklund; Li Yin; Fredrik Granath; Lars Klareskog; Anders Ekbom
Journal:  J Rheumatol       Date:  2002-05       Impact factor: 4.666

6.  High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors.

Authors:  I D del Rincón; K Williams; M P Stern; G L Freeman; A Escalante
Journal:  Arthritis Rheum       Date:  2001-12

Review 7.  Improved health-related quality of life with effective disease-modifying antirheumatic drugs: evidence from randomized controlled trials.

Authors:  Vibeke Strand; Jasvinder A Singh
Journal:  Am J Manag Care       Date:  2007-12       Impact factor: 2.229

8.  Survival, prognosis, and causes of death in rheumatoid arthritis.

Authors:  D M Mitchell; P W Spitz; D Y Young; D A Bloch; D J McShane; J F Fries
Journal:  Arthritis Rheum       Date:  1986-06

9.  Association of mortality with disease severity in rheumatoid arthritis, independent of comorbidity.

Authors:  Gregorio Navarro-Cano; Inmaculada Del Rincón; Samvel Pogosian; José F Roldán; Agustín Escalante
Journal:  Arthritis Rheum       Date:  2003-09

Review 10.  Why do people with rheumatoid arthritis still die prematurely?

Authors:  S E Gabriel
Journal:  Ann Rheum Dis       Date:  2008-12       Impact factor: 19.103

View more
  37 in total

1.  Trends in Hospitalizations for Serious Infections in Patients With Rheumatoid Arthritis in the US Between 1993 and 2013.

Authors:  Sadao Jinno; Na Lu; S Reza Jafarzadeh; Maureen Dubreuil
Journal:  Arthritis Care Res (Hoboken)       Date:  2018-02-18       Impact factor: 4.794

2. 

Authors:  Norbert Wagner; Frauke Assmus; Gabriele Arendt; Erika Baum; Ulrich Baumann; Christian Bogdan; Gerd Burchard; Dirk Föll; Edeltraut Garbe; Jane Hecht; Ulf Müller-Ladner; Tim Niehues; Klaus Überla; Sabine Vygen-Bonnet; Thomas Weinke; Miriam Wiese-Posselt; Michael Wojcinski; Fred Zepp
Journal:  Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz       Date:  2019-04       Impact factor: 1.513

3.  Decreased Cardiovascular Mortality in Patients with Incident Rheumatoid Arthritis (RA) in Recent Years: Dawn of a New Era in Cardiovascular Disease in RA?

Authors:  Elena Myasoedova; Sherine E Gabriel; Eric L Matteson; John M Davis; Terry M Therneau; Cynthia S Crowson
Journal:  J Rheumatol       Date:  2017-04-01       Impact factor: 4.666

Review 4.  Cardiovascular effects of approved drugs for rheumatoid arthritis.

Authors:  Fabiola Atzeni; Javier Rodríguez-Carrio; Călin D Popa; Michael T Nurmohamed; Gabriella Szűcs; Zoltán Szekanecz
Journal:  Nat Rev Rheumatol       Date:  2021-04-08       Impact factor: 20.543

5.  The risk and trend of pulmonary embolism and deep vein thrombosis in rheumatoid arthritis: a general population-based study.

Authors:  Lingyi Li; Na Lu; Ana Michelle Avina-Galindo; Yufei Zheng; Diane Lacaille; John M Esdaile; Hyon K Choi; J Antonio Aviña-Zubieta
Journal:  Rheumatology (Oxford)       Date:  2021-01-05       Impact factor: 7.580

Review 6.  Cardiovascular Disease Risk in Older Adults and Elderly Patients with Rheumatoid Arthritis: What Role Can Disease-Modifying Antirheumatic Drugs Play in Cardiovascular Risk Reduction?

Authors:  Alvin Lee Day; Jasvinder A Singh
Journal:  Drugs Aging       Date:  2019-06       Impact factor: 3.923

7.  All-cause and cause-specific mortality in systemic lupus erythematosus: a population-based study.

Authors:  Bahar Moghaddam; Shelby Marozoff; Lingyi Li; Eric C Sayre; J Antonio Aviña- Zubieta
Journal:  Rheumatology (Oxford)       Date:  2021-12-24       Impact factor: 7.580

Review 8.  Myocardial Dysfunction and Heart Failure in Rheumatoid Arthritis.

Authors:  Elizabeth Park; Jan Griffin; Joan M Bathon
Journal:  Arthritis Rheumatol       Date:  2021-12-27       Impact factor: 10.995

9.  Mortality rate in rheumatoid arthritis-related interstitial lung disease: the role of radiographic patterns.

Authors:  Maria A Nieto; Maria J Rodriguez-Nieto; Olga Sanchez-Pernaute; Fredeswinda Romero-Bueno; Leticia Leon; Cristina Vadillo; Dalifer D Freites-Nuñez; Juan A Jover; Jose L Álvarez-Sala; Lydia Abasolo
Journal:  BMC Pulm Med       Date:  2021-06-30       Impact factor: 3.317

Review 10.  Body composition in patients with rheumatoid arthritis: a narrative literature review.

Authors:  Jean-Guillaume Letarouilly; René-Marc Flipo; Bernard Cortet; Anne Tournadre; Julien Paccou
Journal:  Ther Adv Musculoskelet Dis       Date:  2021-06-21       Impact factor: 5.346

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.